Next-Generation Immune Checkpoint Inhibitors

Who are the Market Top Companies and What are Their Offerings?

What are the Recent Developments in the Market?

• In April 2026, a collaboration between BostonGene and ImmunoGenesis was announced for the accelerated clinical development of IMGS-001, which is a cytotoxic immune checkpoint inhibitor targeting both PD-L1 and PD-L2. They will investigate its effect on each patient’s comprehensive immune and genetic profile, where it is under phase 1a/b dose-escalation and dose-expansion safety and efficacy trial for patients with solid tumors.
• In January 2026, the accelerated approval from the Saudi Food and Drug Authority for the combination of ANKTIVA and an immune checkpoint inhibitor was granted for the treatment of metastatic non-small cell lung cancer. This combination represents the world’s first approved subcutaneously administered IL-15 receptor superagonist and chemotherapy-free immunotherapy, activating natural killer cells and killer T cells, restoring the immune competence.

Market Value Chain Analysis

R&D

• The R&D of the next generation immune checkpoint inhibitors focuses on the development of new bispecific antibodies and novel target discovery.
• Key players: Bristol Myers Squibb, Roche, Merck & Co.

Clinical Trials and Regulatory Approvals

• The objective response rate, progression-free survival, and overall survival are evaluated in the clinical trials and regulatory approvals of the next-generation immune checkpoint inhibitors.
• Key players: Bristol Myers Squibb, Roche, Merck & Co.

Patient Support and Services

• Nursing support, copay assistance, and reimbursement navigation are provided in the patient support and services of the next-generation immune checkpoint inhibitors.
• Key players: Bristol Myers Squibb, Merck & Co., Genentech.

Market Growth

The global next-generation immune checkpoint inhibitors market size was estimated at USD 28.6 billion in 2025 and is predicted to increase from USD 32.55 billion in 2026 to approximately USD 104.18 billion by 2035, expanding at a CAGR of 13.8% from 2026 to 2035.